RE:christophes liked article on linked inAscidian’s worldwide deal with Roche, of Basel, Switzerland, to discover and develop RNA exon editing therapeutics for neurological diseases, includes $42 million in an up-front payment, as well as up to $1.8 billion in research, clinical and commercial milestone payments, plus royalties. Roche gains exclusive, targetspecific rights to Ascidian’s technology for undisclosed neurological targets. Ascidian retains rights to develop programs against other neurological targets, either internally or with another partner. The deal is Ascidian’s first major partnership
This is the kind of deal oncolytics need